Technical Forum: Small-Molecule Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Technical Forum: Small-Molecule Synthesis
Pharmaceutical Technology gains insight into approaches for producing aromatic amines.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 48-50

References

1. R.N. Salvatore, C. H. Yoon, and K.W. Jung, Tetrahedron 57 (10) 7785–7811 (2001).

2. Y. Watanabe et al., Tetrahedron Lett. 22 (28), 2667–2670 (1981).

3. Y. Watanabe et al., J. Org. Chem. 49 (18), 3359–3363 (1984).

4. Y. Watanabe et al., J. Org. Chem. 61 (13), 4214–4218 (1996).

5. C. Jun et al., Chem. Commun. 13, 1405–1406 (1998).

6. R.A.T.M. Abbenhuis, J. Boersma, and G. van Koten, J. Org. Chem. 63 (13), 4282–4290 (1998).

7 T. Naota, H. Takaya, and S.I. Murahashi, Chem. Rev. 98 (7), 2599–2660 (1998).

8. R. Grigg et al. J. Chem. Soc. Chem. Commun. 12, 611–612 (1981).

9. G. Cami Kobeci, and J.M. Williams. J. Chem. Soc. Commun., 1072–1073 (2004).

10. K.I. Fujita and R. Yamaguchi, Synlett. 4, 560–571 (2005).

11. R. Yamaguchi et al., Org. Lett. 10 (2) 181–184 (2008).

12. D. Hollmann et al., Angew. Chem. Int. Ed. 46 (43), 8291–8294 (2007).

13. A. Tillack et al., Tetrahedron Lett. 47 (50), 8881–8885 (2006).

14. K. Fujita, Y. Enoki, and R. Yamaguchi, Tetrahedron 64 (8), 1943–1954 (2008).

15. M.H Hamid et al., J. Am. Chem. Soc. 131 (5), 1766–1774 (2009).

16. T.E. Müller and M. Beller, Chem. Rev. 98 (2), 675–704 (1998).

17. M. Beller et al., Chem. Eur. J. 5 (4), 1306–1319 (1999).

18. M. Nobis and B. Driessen-Hölscher, Angew. Chem., Int. Ed. 40 (21), 3983–3985 (2001).

19. M. Utsunomiya et al., J. Am. Chem. Soc. 125 (19), 5608–5609 (2003).

20. J.S. Ryu, G.Y. Li, and T.J.J. Marks, J. Am. Chem. Soc. 125 (19), 12584–12605 (2003).

21. A.M. Johns et al., J. Am. Chem. Soc. 128 (6) 1828–1839 (2006).

22. D. Chan et al., Tetrahedron Lett. 39 (19), 2933–2936 (1998).

23. D.A. Evans, J.L. Katz, and T.R. West, Tetrahedron Lett. 39 (19) 2937–2940 (1998).

24. P.Y.S. Lam, et al., Tetrahedron Lett. 39 (19) 2941–2944 (1998).

25. P.Y.S. Lam et al., Synlett. 5, 674–676 (2000).

26. J.P. Collman and M. Zhong, Org. Lett. 2 (9), 1233–1236 (2000).

27. J.C. Antilla and S.L. Buchwald, Org. Lett. 3 (13), 2077–2079 (2001).

28. P.Y.S. Lam et al., Tetrahedron Lett. 42 (20), 3415–3453 (2001).

29. C. Moessner and C. Bolm, Org. Lett. 7 (13), 2667–2669 (2005).

30. J.B. Lan et al., Synlett. 6, 1095–1097 (2004).

31. B. Sreedhar et al., Synthesis 5, 795–799 (2008).

32. T. Tsuritaniet et al., Org. Lett. 10 (8), 1653–1665 (2008).

33. S. Bérnard, L. Neuville, and J. Zhu, J. Org. Chem. 73 (16) 6441–6444 (2008).

34. Boronic Acids, D.G. Hall, Ed., (1st Edition, Wiley-VCH, Weinheim, Germany, 2005).

35. I. González et al., Org. Lett. 11 (8) 1677–1680 (2009).

36. M. Larrosa et al., Synlett., 14, 2101–2105, (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here